Tech Company Financing Transactions
TolerRx Funding Round
On 8/16/2006, TolerRx raised $35.6 million in Series E funding from Bear Stearns Health Innoventures, HealthCare Ventures and Mesirow Financial.
Transaction Overview
Company Name
Announced On
8/16/2006
Transaction Type
Venture Equity
Amount
$35,600,000
Round
Series E
Investors
Proceeds Purpose
The funds will support the clinical development of TolerRx's lead product, TRX4, an anti-CD3 monoclonal antibody in development for Type 1 diabetes and psoriasis.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
300 Technology Square 3rd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
TolerRx is a biopharmaceutical company specializing in the discovery and development of therapies that induce and maintain immunological tolerance and reprogram the immune system to treat patients with immune-related diseases
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Ringler
Browse more venture capital transactions:
Prev: 8/16/2006: Acura Pharmaceuticals venture capital transaction
Next: 8/16/2006: Boingo Wireless venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs